Hillstream BioPharma (HILS) Stock Price, News & Analysis

Company Overview

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Key Stats

• Today's Range: $1.97 to $1.99
• 50-Day Range: $0.23 to $2.50
• 52-Week Range: $0.19 to $2.65
• Volume: 16,798 shs
• Average Volume: 1.39 million shs
• Market Capitalization: $35.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HILS Stock Analysis - Frequently Asked Questions

How have HILS shares performed this year?

Hillstream BioPharma's stock was trading at $2.06 at the beginning of the year. Since then, HILS stock has decreased by 2.4% and is now trading at $2.01.
View the best growth stocks for 2025 here.

When did Hillstream BioPharma IPO?

Hillstream BioPharma (HILS) raised $21 million in an initial public offering (IPO) on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share.

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hillstream BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hillstream BioPharma investors own include Absci (ABSI), Luminar Technologies (LAZR), Agnico Eagle Mines (AEM), Amprius Technologies (AMPX), Atai Life Sciences (ATAI), BioTelemetry (BEAT) and BioSig Technologies (BSGM).

Company Calendar

• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HILS
• CUSIP: N/A
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -188.44%
• Return on Assets: -149.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.01
• Quick Ratio: 3.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 4.19

Miscellaneous

• Outstanding Shares: 17,603,000
• Free Float: 12,280,000
• Market Cap: $35.38 million
• Optionable: Not Optionable
• Beta: 3.08